ArticleClinical lymphoma, myeloma & leukemia2025

Indirect Comparison of Epcoritamab Versus Axicabtagene Ciloleucel in Chimeric Antigen Receptor T-Cell-Eligible and -Naive Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Gilles Salles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.